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INVITED COMMENTARY
The article by Steinacker and colleagues provides
new insights into the pathophysiology of peripheral
arterial disease (PAD). PAD is associated with major
impairments in limb function. Patients with claudica-
tion have reduced exercise performance because of
skeletal ischemia during exercise. This leads to marked
limitations in daily walking activity, and thus, patients
are unable to meet the physical function demands of
daily activities. In contrast, patients with critical leg
ischemia have reduced blood flow at rest, which there-
fore leads to symptoms of ischemic rest pain, ulcera-
tion, and gangrene. These individuals have restricted
ambulation, poor muscle function, inability to heal
distal lesions, and they are at risk of limb loss.
The pathophysiology of the clinical manifesta-
tions of PAD is initiated by the reduction in limb
blood flow as the result of atherosclerotic occlusion
of the major conduit vessels to the lower extremity.
In patients with claudication, the metabolic demand
of lower extremity skeletal muscle is relatively low at
rest. Patients with claudication have adequate perfu-
sion to skeletal muscle, skin, and other tissues in the
leg to maintain healthy resting metabolic rates.
However, with exercise, there is a marked increase in
skeletal muscle metabolism that in healthy individu-
als results in a 20-fold to 40-fold increase in skeletal
muscle blood flow and oxygen delivery.1 In contrast,
patients with claudication have blood flow that is
unable to appropriately increase during exercise,
which results in a supply-demand mismatch that
leads to skeletal muscle ischemia.1 Although the ini-
tial insult in the patient with claudication is clearly
hemodynamic, the severity of the symptom cannot
be totally explained by reduced blood flow alone. For
example, measurements of calf blood flow or ankle
blood pressure do not correlate well with treadmill
exercise performance.2,3 Thus, other factors that
affect skeletal muscle metabolism and function must
also play a significant role in determining the clinical
severity of claudication.
During daily ambulatory activity, patients with
claudication have several episodes of skeletal muscle
ischemia followed by reperfusion when they stop
and rest to relieve the claudication pain. This then
leads to an increase in oxidant stress and the poten-
tial for free radical injury to skeletal muscle.4 Several
studies have evaluated these concepts with the
assessment of changes in skeletal muscle in PAD
with the muscle biopsy technique. In particular,
patients with unilateral disease were selected for
study to allow comparisons between the affected and
unaffected legs. The results of these studies have
shown that, in patients with claudication, there is
marked evidence of skeletal muscle denervation of
the distal motor nerves of the gastrocnemius mus-
cle.5,6 The denervation is confined to the affected
limb and is associated with skeletal muscle atrophy
and weakness.
In addition to muscle denervation, a number of
metabolic abnormalities have also been described in
the affected muscles of patients with claudication.
Muscle mitochondria are the cellular site of oxida-
tive energy production for muscle contraction. PAD
is associated with mitochondrial DNA injury and
altered expression of mitochondrial enzyme activi-
ties.7 Further evidence of impaired metabolism
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comes from the observations of changes in skeletal
muscle carnitine metabolism. Carnitine is an impor-
tant cofactor that provides a buffer molecule for the
acyl-CoA pool. During healthy metabolic condi-
tions, there is a rapid flux and turnover as fatty acids,
proteins, and carbohydrates are converted to acyl-
CoA intermediates to be used in the Krebs cycle for
further oxidative metabolism. During skeletal mus-
cle ischemia, this process is interrupted, which leads
to the accumulation of acyl-CoA intermediates.8
This then leads to the formation of acylcarnitines.
For example, the accumulation of acylcarnitines has
been observed in ischemic skeletal muscle in patients
with claudication.8 Further, patients with the great-
est accumulation had the lowest treadmill exercise
performance. Thus, alterations in skeletal muscle
neurologic and metabolic function provide insight
into the pathophysiology of the disease. The
reduced skeletal muscle blood flow is an initial
event, but ischemic injury leads to a more compli-
cated and disabling clinical scenario.
The study by Steinacker and colleagues extends
these findings with the evaluation of changes in
skeletal muscle myosin isoforms in the different clin-
ical stages of PAD. Skeletal muscle isoforms in part
determine the different muscle fiber types that can
be divided into two major categories. Type I oxida-
tive, slow twitch fibers have large numbers of mito-
chondria and are used to sustain repetitive muscle
contractions under aerobic conditions over long
periods of time. In contrast, type II glycolytic, fast
twitch fibers have fewer mitochondria but generate
more force during contraction. These fibers are used
to produce rapid muscle contractions but have easy
fatigability. Thus, changes in skeletal muscle iso-
forms may be important in terms of understanding
how skeletal muscle adapts to chronic ischemia.
Steinacker and colleagues observed that the type
I myosin isoform was increased in both Fontaine
stage 3 and 4 and was associated with a correspond-
ing decrease in type IIb isoforms in the same
patients. In contrast, type IIa isoforms were reduced
only in Fontaine stage 4. These results are consistent
with previous histologic study results that show a
decrease in type 2 skeletal muscle fibers in patients
with claudication.5
Although these studies are provocative, there are
several limitations to the observations. Patients were
mainly enrolled with different clinical grades of sever-
ity. What is lacking is any functional correlation to the
differences in muscle isoforms. This would be particu-
larly important to determine whether the changes in
muscle isoforms are associated with reduced muscle
strength and muscle performance. Also limiting is the
inability to distinguish whether the changes in muscle
isoforms result from reduced blood flow per se or
other factors, such as age, inactivity, and oxidant stress.
In summary, PAD in fact has a complex patho-
physiology. The clinical manifestations are initiated
in claudicants by decreased oxygen delivery during
exercise and in critical leg ischemia by reduced flow
at rest. However, the disease pathophysiology is not
simply explained by reductions in flow. Alterations in
the skeletal muscle end organ are critically important
in defining the functional limitations of the patient.
Future studies need to further explore these changes
in skeletal muscle to define whether they may serve
as new targets for therapeutic interventions.
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Please see the related article by Dr Jürgen M.
Steinacker et al on pages 443-9.
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